Payment overview · 2025
General Payments
$55.32
3 reported records · 3 companies
Healthcare provider profile · identity verified
William R Powers, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · BECKLEY, WV · NPI 1871601377
Verified facts
What the public records show
CMS Open Payments records show William R Powers, DO received $55.32 in general payments during 2025 across 3 reported records.
Novartis Pharmaceuticals Corporation accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Farxiga by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.41 | 35.1% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $18.22 | 32.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.69 | 32.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $55.32 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
92 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 622 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 499 | 46 |
| Eliquis | Apixaban | 344 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 315 | 18 |
| Famotidine | Famotidine | 312 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 279 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 25 |
| Furosemide | Furosemide | 250 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 17 |
| Sertraline Hcl | Sertraline Hcl | 193 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 22 |
| Carvedilol | Carvedilol | 169 | 11 |
| Donepezil Hcl | Donepezil Hcl | 163 | 12 |
| Lisinopril | Lisinopril | 163 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 158 | suppressed |
| Mirtazapine | Mirtazapine | 156 | suppressed |
| Potassium Chloride | Potassium Chloride | 151 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 12 |
| Simvastatin | Simvastatin | 123 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 11 |
| Gabapentin | Gabapentin | 117 | 21 |
| Metformin Hcl | Metformin Hcl | 116 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 115 | suppressed |
| Omeprazole | Omeprazole | 106 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 24 |
| Risperidone | Risperidone | 101 | suppressed |
| Allopurinol | Allopurinol | 98 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 92 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 91 | 12 |
| Jardiance | Empagliflozin | 88 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 12 |
| Sucralfate | Sucralfate | 88 | 12 |
| Divalproex Sodium | Divalproex Sodium | 87 | suppressed |
| Levetiracetam | Levetiracetam | 87 | suppressed |
| Memantine Hcl | Memantine Hcl | 79 | suppressed |
| Losartan Potassium | Losartan Potassium | 78 | suppressed |
| Spironolactone | Spironolactone | 76 | suppressed |
| Entresto | Sacubitril/Valsartan | 74 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 72 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 70 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | suppressed |
| Xarelto | Rivaroxaban | 68 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 66 | suppressed |
| Nifedipine Er | Nifedipine | 61 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Lorazepam | Lorazepam | 59 | 12 |
| Prednisone | Prednisone | 57 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 56 | suppressed |
| Tradjenta | Linagliptin | 56 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | suppressed |
| Finasteride | Finasteride | 49 | suppressed |
| Olanzapine | Olanzapine | 49 | suppressed |
| Sotalol | Sotalol Hcl | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 44 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 41 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Multaq | Dronedarone Hcl | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55.32 · 3 records | Novartis Pharmaceuticals Corporation | BREZTRI, CRYSVITA, LEQVIO | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error